Recurrent Novel P2RY8/IGH Translocations in B-Lymphoblastic Leukemia/Lymphoma

Yanglan Fang; Man Wang; Shuhong Hu; Tanzhen Wang; Yujie Liu; Jinyan Xiao; Yiming Cai; Ying Wang; Huiying Qiu; Xiaowen Tang; Suning Chen; Depei Wu; Yang Xu; Tianhui Liu

doi:10.3389/fonc.2022.896858

Recurrent Novel P2RY8/IGH Translocations in B-Lymphoblastic Leukemia/Lymphoma

Front Oncol. 2022 Jul 14:12:896858. doi: 10.3389/fonc.2022.896858. eCollection 2022.

Authors

Yanglan Fang^{1

2}, Man Wang¹, Shuhong Hu^{1

2}, Tanzhen Wang^{1

2}, Yujie Liu^{1

2}, Jinyan Xiao^{1

2}, Yiming Cai^{1

2}, Ying Wang¹, Huiying Qiu¹, Xiaowen Tang¹, Suning Chen¹, Depei Wu^{1

2}, Yang Xu^{1

2}, Tianhui Liu^{1

2}

Affiliations

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

Abstract

Translocations involving the immunoglobulin heavy chain (IGH) locus are common abnormalities in B-lymphoblastic leukemia/lymphoma (B-ALL) and multiple myeloma. These rearrangements result in a juxtaposition of IGH enhancers to the vicinity of oncogenes, such as MYC and CRLF2, leading to the upregulation of oncogenes. Here, we identified recurrent novel P2RY8/IGH translocations in three B-ALL patients by transcriptome sequencing. Noncoding exon 1 of P2RY8 was translocated to different sites of the IGH gene, resulting in transcripts of P2RY8/IGHM, P2RY8/IGHV, and P2RY8/IGHD. However, a high expression level of truncated P2RY8 was observed in the patients compared with healthy donors, which might be related to the aggressive clinical course and inferior outcome. In summary, we described recurrent novel P2RY8/IGH translocations with high expression levels of P2RY8, which may contribute to the guidelines for clinical diagnosis and treatment.

Keywords: B-lymphoblastic leukemia/lymphoma; IGH; P2RY8; fusion gene; translocation.